Home | Business News | Browse by Publication | M | Medical Letter on the CDC & FDA

Impax Pharmaceuticals Initiates Second Phase III Trial of IPX066 in Parkinson's Disease.

Publication: Medical Letter on the CDC & FDA
Publication Date: 15-NOV-09
Format: Online
Delivery: Immediate Online Access

Article Excerpt
Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ:IPXL), announced that it has initiated a multinational Phase III trial of its late-stage drug candidate IPX066 in advanced Parkinson's disease (PD) patients. IPX066 is an investigational extended release carbidopa-levodopa product intended to rapidly achieve and then sustain effective blood concentrations of levodopa, potentially improving PD clinical symptom management. This is the second of two Phase III studies designed to support marketing approval of IPX066 in Parkinson's disease. Impax Pharmaceuticals previously reported in June the initiation of the first Phase III study of IPX066 in naive...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.